Patents by Inventor Nabeel Bardeesy

Nabeel Bardeesy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of diagnosing and prognosing lung cancer
    Patent number: 11009508
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 18, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, Board of Regents of the University of Texas System
    Inventors: Kwok-Kin Wong, Bruce E. Johnson, Pasi A. Janne, Hongbin Ji, Nabeel Bardeesy, Norman E. Sharpless, Diego H. Castrillon
  • Plectin-1 Targeted Agents for Detection and Treatment of Pancreatic Ductal Adenocarcinoma
    Publication number: 20190209715
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticies conjugated to peptide ligands for identifying PDACs.
    Type: Application
    Filed: November 9, 2018
    Publication date: July 11, 2019
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER
    Publication number: 20190145977
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: January 23, 2019
    Publication date: May 16, 2019
    Inventors: Kwok-Kin WONG, Bruce E. JOHNSON, Pasi A. JANNE, Hongbin JI, Nabeel BARDEESY, Norman E. SHARPLESS, Diego H. Castrillon
  • Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
    Patent number: 10124077
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignee: The General Hospital Corporation
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Plectin-1 Targeted Agents for Detection and Treatment of Pancreatic Ductal Adenocarcinoma
    Publication number: 20170087257
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Application
    Filed: June 8, 2016
    Publication date: March 30, 2017
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
    Patent number: 9387265
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 12, 2016
    Assignee: The General Hospital Corporation
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Plectin-1 Targeted Agents for Detection and Treatment of Pancreatic Ductal Adenocarcinoma
    Publication number: 20150151010
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Application
    Filed: September 8, 2014
    Publication date: June 4, 2015
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
    Patent number: 8829159
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: September 9, 2014
    Assignee: The General Hospital Corporation
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • METHOD FOR TREATING CANCER BY INCREASING AMP-ACTIVATED KINASE ACTIVITY
    Publication number: 20120122991
    Abstract: The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer.
    Type: Application
    Filed: January 20, 2012
    Publication date: May 17, 2012
    Applicants: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Lewis C. Cantley, Reuben J. Shaw, Nabeel Bardeesy, Ronald A. Depinho
  • PLECTIN-1 TARGETED AGENTS FOR DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA
    Publication number: 20110182814
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Application
    Filed: April 14, 2009
    Publication date: July 28, 2011
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER
    Publication number: 20110119776
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: February 4, 2008
    Publication date: May 19, 2011
    Inventors: Kwok-Kin Wong, Bruce Johnson, Pasi Janne, Hongbin Ji, Nabeel Bardeesy, Norman Sharpless
  • Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
    Publication number: 20080194019
    Abstract: The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer.
    Type: Application
    Filed: September 4, 2004
    Publication date: August 14, 2008
    Applicants: Beth Israel Deaconess Medical Center, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Lewis C. Cantley, Reuben J. Shaw, Nabeel Bardeesy, Ronald A. Depinho